Morgan Stanley’s Atossa Therapeutics ATOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $85.2K | Buy |
16,202
+12,102
| +295% | +$76.6K | ﹤0.01% | 6226 |
|
|
2025
Q4 | $36.3K | Sell |
4,100
-3,390
| -45% | -$42.9K | ﹤0.01% | 6527 |
|
|
2025
Q3 | $97.4K | Sell |
7,490
-3,237
| -30% | -$40K | ﹤0.01% | 6164 |
|
|
2025
Q2 | $134K | Sell |
10,727
-8,219
| -43% | -$98.3K | ﹤0.01% | 6026 |
|
|
2025
Q1 | $191K | Sell |
18,946
-11,200
| -37% | -$136K | ﹤0.01% | 5745 |
|
|
2024
Q4 | $427K | Sell |
30,146
-355
| -1% | -$6.93K | ﹤0.01% | 5491 |
|
|
2024
Q3 | $695K | Buy |
30,501
+91
| +0.3% | +$1.84K | ﹤0.01% | 5241 |
|
|
2024
Q2 | $543K | Sell |
30,410
-20,618
| -40% | -$456K | ﹤0.01% | 5255 |
|
|
2024
Q1 | $1.38M | Buy |
51,028
+35,721
| +233% | +$574K | ﹤0.01% | 4797 |
|
|
2023
Q4 | $202K | Buy |
15,307
+5,323
| +53% | +$57.4K | ﹤0.01% | 5944 |
|
|
2023
Q3 | $110K | Sell |
9,984
-3,075
| -24% | -$44.6K | ﹤0.01% | 5853 |
|
|
2023
Q2 | $247K | Buy |
13,059
+1,675
| +15% | +$20.3K | ﹤0.01% | 5548 |
|
|
2023
Q1 | $124K | Sell |
11,384
-1,529
| -12% | -$17.1K | ﹤0.01% | 5928 |
|
|
2022
Q4 | $102K | Buy |
12,913
+659
| +5% | +$7.57K | ﹤0.01% | 5964 |
|
|
2022
Q3 | $152K | Sell |
12,254
-5,505
| -31% | -$79.9K | ﹤0.01% | 5867 |
|
|
2022
Q2 | $291K | Buy |
17,759
+7,919
| +80% | +$125K | ﹤0.01% | 5703 |
|
|
2022
Q1 | $184K | Sell |
9,840
-424
| -4% | -$8.61K | ﹤0.01% | 5972 |
|
|
2021
Q4 | $246K | Sell |
10,264
-5,611
| -35% | -$205K | ﹤0.01% | 5955 |
|
|
2021
Q3 | $776K | Sell |
15,875
-4,923
| -24% | -$286K | ﹤0.01% | 5215 |
|
|
2021
Q2 | $1.97M | Buy |
20,798
+7,616
| +58% | +$403K | ﹤0.01% | 4650 |
|
|
2021
Q1 | $418K | Buy |
13,182
+13,180
| +659,000% | +$482K | ﹤0.01% | 5249 |
|
|
2020
Q4 | $0 | Sell |
2
-8,768
| -100% | -$203K | ﹤0.01% | 7032 |
|
|
2020
Q3 | $318K | Buy |
8,770
+8,763
| +125,186% | +$421K | ﹤0.01% | 4871 |
|
|
2020
Q2 | $0 | Hold |
7
| – | – | ﹤0.01% | 6587 |
|
|
2020
Q1 | $0 | Hold |
7
| – | – | ﹤0.01% | 6560 |
|
|
2019
Q4 | $0 | Hold |
7
| – | – | ﹤0.01% | 6640 |
|
|
2019
Q3 | $0 | Sell |
7
-120
| -94% | -$3.8K | ﹤0.01% | 6628 |
|
|
2019
Q2 | $5K | Sell |
127
-32
| -20% | -$1.28K | ﹤0.01% | 6301 |
|
|
2019
Q1 | $8K | Buy |
159
+93
| +141% | +$2.71K | ﹤0.01% | 6231 |
|
|
2018
Q4 | $1K | Buy |
+66
| New | +$1.31K | ﹤0.01% | 6479 |
|
|
2017
Q4 | – | Sell |
-1
| Closed | – | – | 6563 |
|
|
2017
Q3 | $0 | Buy |
+1
| New | +$79 | ﹤0.01% | 6527 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6501 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6562 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 6656 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 6604 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 6637 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 6543 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 6560 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 6563 |
|
|
2014
Q2 | – | Sell |
-4
| Closed | -$15.6K | – | 6509 |
|
|
2014
Q1 | $19K | Buy |
+4
| New | +$23.7K | ﹤0.01% | 5973 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 6248 |
|
Other funds holding ATOS
VCM
VFT
Morgan Stanley's ATOS Position: Q1 2026 in Review
Morgan Stanley increased its Atossa Therapeutics (ATOS) stake by 295% in Q1 2026, buying an estimated $76.6K and bringing the position to 16,202 shares worth $85.2K. The position accounts for ﹤0.01% of the portfolio, ranked #6226.
Morgan Stanley first reported a position in ATOS in Q1 2014 and has held it in 32 quarters since. The position peaked at $1.97M in Q2 2021. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.
- Morgan Stanley held 16,202 shares of Atossa Therapeutics worth $85.2K as of Q1 2026.
- Morgan Stanley bought 12,102 Atossa Therapeutics shares in Q1 2026, an estimated $76.6K.
- Atossa Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6226 holding.
- Morgan Stanley first reported a position in Atossa Therapeutics in Q1 2014 and has held it in 32 quarters since.
- Morgan Stanley's Atossa Therapeutics position peaked at $1.97M in Q2 2021.
- 33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.